Kymera Therapeutics (KYMR) announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Cautious Hold Rating on Kymera Therapeutics Amid Promising KT-621 Prospects and Strategic Developments
- Kymera Therapeutics initiated with a Buy at Citi
- Kymera Therapeutics: Leading the Way with Innovative STAT6 Degrader KT-621
- Kymera Therapeutics: Promising Prospects in STAT6 Targeting with KT-621
- Kymera Therapeutics Grants Performance Stock Units to Executives